Abstract
Since 1993, with the advent of felbamate, physicians have been blessed with the addition of eight new antiepileptic medications for the treatment of epilepsy. Increasing evidence is accumulating that these drugs are effective as monotherapy agents. The use of monotherapy minimizes side effects, and newer drugs have fewer interactions than many of the older antiepileptic medications with comparable efficacy. Using the newer antiepileptic agents in monotherapy, even as an initial therapy would appear to be an appropriate clinical decision.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
